203 related articles for article (PubMed ID: 26306523)
1. The financial hazard of personalized medicine and supportive care.
Carrera PM; Olver I
Support Care Cancer; 2015 Dec; 23(12):3399-401. PubMed ID: 26306523
[TBL] [Abstract][Full Text] [Related]
2. The financial burden and distress of patients with cancer: Understanding and stepping-up action on the financial toxicity of cancer treatment.
Carrera PM; Kantarjian HM; Blinder VS
CA Cancer J Clin; 2018 Mar; 68(2):153-165. PubMed ID: 29338071
[TBL] [Abstract][Full Text] [Related]
3. Let's Talk About Financial Toxicities.
Katz A
Oncol Nurs Forum; 2018 May; 45(3):281-282. PubMed ID: 29683119
[TBL] [Abstract][Full Text] [Related]
4. Current practice in and considerations for personalized medicine in lung cancer: From the patient's molecular biology to patient values and preferences.
Carrera PM; Ormond M
Maturitas; 2015 Sep; 82(1):94-9. PubMed ID: 25981825
[TBL] [Abstract][Full Text] [Related]
5. [Should inoperable pulmonary cancer be treated?].
Klastersky J
Rev Med Brux; 1993 Apr; 14(4):102-9. PubMed ID: 7684850
[TBL] [Abstract][Full Text] [Related]
6. Lung cancer management concerns in New Zealand.
Garrett J
N Z Med J; 2004 Jun; 117(1196):U929. PubMed ID: 15280933
[No Abstract] [Full Text] [Related]
7. Assessing the economic value of anticancer therapies.
Neymark N
Recent Results Cancer Res; 1998; 148():1-285. PubMed ID: 9670279
[No Abstract] [Full Text] [Related]
8. A Retrospective Analysis of Precision Medicine Outcomes in Patients With Advanced Cancer Reveals Improved Progression-Free Survival Without Increased Health Care Costs.
Haslem DS; Van Norman SB; Fulde G; Knighton AJ; Belnap T; Butler AM; Rhagunath S; Newman D; Gilbert H; Tudor BP; Lin K; Stone GR; Loughmiller DL; Mishra PJ; Srivastava R; Ford JM; Nadauld LD
J Oncol Pract; 2017 Feb; 13(2):e108-e119. PubMed ID: 27601506
[TBL] [Abstract][Full Text] [Related]
9. Addressing the Financial Burden of Cancer Clinical Trial Participation: Longitudinal Effects of an Equity Intervention.
Nipp RD; Lee H; Gorton E; Lichtenstein M; Kuchukhidze S; Park E; Chabner BA; Moy B
Oncologist; 2019 Aug; 24(8):1048-1055. PubMed ID: 30988039
[TBL] [Abstract][Full Text] [Related]
10. Economic analysis of the TAX 317 trial: docetaxel versus best supportive care as second-line therapy of advanced non-small-cell lung cancer.
Leighl NB; Shepherd FA; Kwong R; Burkes RL; Feld R; Goodwin PJ
J Clin Oncol; 2002 Mar; 20(5):1344-52. PubMed ID: 11870178
[TBL] [Abstract][Full Text] [Related]
11. How should we value lives lost to cancer?
Ramsey SD
J Natl Cancer Inst; 2008 Dec; 100(24):1742-3. PubMed ID: 19066279
[No Abstract] [Full Text] [Related]
12. Palliative care experiences of adult cancer patients from ethnocultural groups: a qualitative systematic review protocol.
Busolo D; Woodgate R
JBI Database System Rev Implement Rep; 2015 Jan; 13(1):99-111. PubMed ID: 26447011
[TBL] [Abstract][Full Text] [Related]
13. Current and projected patient and insurer costs for the care of patients with non-small cell lung cancer in the United States through 2040.
Hess LM; Cui ZL; Wu Y; Fang Y; Gaynor PJ; Oton AB
J Med Econ; 2017 Aug; 20(8):850-862. PubMed ID: 28532187
[TBL] [Abstract][Full Text] [Related]
14. Estimating the cost of lung cancer diagnosis and treatment in Canada: the POHEM model.
Evans WK; Will BP; Berthelot JM; Wolfson MC
Can J Oncol; 1995 Dec; 5(4):408-19. PubMed ID: 8770457
[TBL] [Abstract][Full Text] [Related]
15. Evaluating Expected Costs and Benefits of Granting Access to New Treatments on the Basis of Progression-Free Survival in Non-Small-Cell Lung Cancer.
Lakdawalla DN; Chou JW; Linthicum MT; MacEwan JP; Zhang J; Goldman DP
JAMA Oncol; 2015 May; 1(2):196-202. PubMed ID: 26181023
[TBL] [Abstract][Full Text] [Related]
16. Cost analysis of cryotherapy for metastatic disease.
Ray CE
J Vasc Interv Radiol; 2012 Jun; 23(6):778-9. PubMed ID: 22626268
[No Abstract] [Full Text] [Related]
17. A growing side effect of cancer care: Financial toxicity: Researchers are taking a closer look at the financial ruin and other disastrous consequences that can accompany escalating costs of cancer care.
Nelson B
Cancer Cytopathol; 2019 Nov; 127(11):673-674. PubMed ID: 31710419
[No Abstract] [Full Text] [Related]
18. Concrete options and ideas for increasing value in oncology care: the view from one trench.
Smith TJ; Hillner BE
Oncologist; 2010; 15 Suppl 1():65-72. PubMed ID: 20237220
[TBL] [Abstract][Full Text] [Related]
19. Economic Benefits of Palliative Care Consultation Continue to Unfold.
Sher DJ
J Clin Oncol; 2015 Sep; 33(25):2723-4. PubMed ID: 26195704
[No Abstract] [Full Text] [Related]
20. Addressing the Financial Burden of Cancer Treatment: From Copay to Can't Pay.
Shankaran V; Ramsey S
JAMA Oncol; 2015 Jun; 1(3):273-4. PubMed ID: 26181165
[No Abstract] [Full Text] [Related]
[Next] [New Search]
